Cullinan Therapeutics, Inc.

CGEM · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.4%

Institutions112.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2013-12-31	2012-09-30
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	$0	$18.94M	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$241.65M	-$196.92M	$144.65M	-$67.95M	-$674864	–
Operating income as a percentage of revenue.	–	–	–	-358.7%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$0	-$192000	-$2.02M	-$1.92M	-$680493	–
Net income divided by the number of shares outstanding — profit attributable to each share.	$-36.93	$-30.56	$2.46	$-1.52	$0.00	–
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-36.93	$-30.56	$2.38	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2013-12-31	2012-09-30
Cash and highly liquid short-term investments the company can access almost immediately.	$88.33M	$83.00M	$156.15M	$59.77M	–	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$448.37M	$621.82M	$561.12M	$437.19M	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$39.64M	$31.50M	$26.09M	$11.81M	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$408.73M	$590.33M	$535.03M	$424.97M	–	–

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2013-12-31	2012-09-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$175.75M	-$145.30M	-$126.66M	-$43.43M	-$669811	-$144288
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$49000	$0	$1.13M	–	–	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$175.80M	-$145.30M	-$127.80M	–	–	–

	You	Peer avg
Revenue Growth	–	+31.0%
ROE	-50.3%	-57.7%

Cullinan Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison